A medical food in mild Alzheimer's disease

( the first clinical trial evaluating the efficacy, tolerability, and safety of a medical food )

Please Help Support Alzheimer's Research Today! 
Your Alzheimer's donation will help billions live without it.
DONATE NOW

To investigate the effect of a medical food on cognitive function in people with mild Alzheimer's disease (AD). A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the delayed verbal recall task of the Wechsler Memory Scale-revised, and the 13-item modified Alzheimer's Disease Assessment Scale-cognitive subscale at week 12. 
At 12 weeks, significant improvement in the delayed verbal recall task was noted in the active group compared with control (P = .021). Modified Alzheimer's Disease Assessment Scale-cognitive subscale and other outcome scores (e.g., Clinician Interview Based Impression of Change plus Caregiver Input, 12-item Neuropsychiatric Inventory, Alzheimer's disease Co-operative Study-Activities of Daily Living, Quality of Life in Alzheimer's Disease) were unchanged. The control group neither deteriorated nor improved. Compliance was excellent (95%) and the product was well tolerated. 
Supplementation with a medical food including phosphatide precursors and cofactors for 12 weeks improved memory (delayed verbal recall) in mild AD patients. This proof-of-concept study justifies further clinical trials. 2010 The Alzheimer's Association. To get more: http://www.sciencedirect.com

TODAY'S PHOTO

The links between EPA and DHA levels and triglycerides and HDL

Intakes of omega-3 exceeding levels consumed by the general US population may significantly reduce the risk of chronic disease, suggests a new study with Yup'ik Eskimos.  ... http://www.nutraingredients.com

Беларусь ТВ

Posted YVN (AMYLOID @ PHOTO)